TDO2 and neoplasm: Tumour necrosis factor receptor-associated factor 7 (TRAF7) and AKT1 mutations in skull base meningiomas increase TDO2 expression in these tumours enabling suppression of immune responses.78 Apart from mutations, oncoviruses also appear to modulate TDO2 expression.